论文部分内容阅读
应用清肝化瘀口服液治疗小剂量CCl_4诱导的肝纤维化大鼠，并与正常对照组、CCl_4模型组、自然恢复组、秋水仙碱治疗组对照。对各组肝脏Ⅰ、Ⅲ、Ⅳ、Ⅴ型胶原及结蛋白进行免疫组化染色和计算机图像分析，并用电镜观察肝脏超微结构的变化。结果发现，清肝化瘀口服液可抑制肝细胞变性坏死，减轻炎症反应，改善微循环，抑制Ⅰ、Ⅲ、Ⅳ、Ⅴ型胶原及结蛋白在肝内的沉积，并可使已形成的胶原重新溶解和吸收，使肝纤维化逆转，效果优于秋水仙碱（P＜0．01）；同时，CCl_4诱导的大鼠肝纤维化可有一定程度的自然恢复。表明清肝化瘀口服液对大鼠肝纤维化有显著的治疗作用。
Low-dose CCl_4-induced hepatic fibrosis in rats was treated with Qinggan Huayu Oral Liquid and compared with normal control group, CCl_4 model group, natural recovery group, and colchicine group. Immunohistochemical staining and computer image analysis of liver I, III, IV, and V collagen and desmin were performed on each group, and the ultrastructure of the liver was observed by electron microscopy. The results showed that Qinggan Huayu Oral Liquid can inhibit degeneration and necrosis of hepatocytes, reduce inflammation, improve microcirculation, inhibit the deposition of type I, III, IV, and V collagens and desmin in the liver, and enable the formation of collagen. Re-dissolution and absorption, reversal of liver fibrosis, the effect is better than colchicine (P <0.01); at the same time, CCl_4 induced liver fibrosis in rats can have a certain degree of natural recovery. Show that Qinggan Huayu Oral Liquid has a significant therapeutic effect on liver fibrosis in rats.